Gene editing efficiency in Jurkat cells using ABE8e RNP
High A to G conversion across different doses
ABE8e protein effectively knocks out B2M protein
IVD Raw Materials
Catalog Products » Next-Generation Gene Editing: Base Editor and Prime Editor
Base editing and prime editing represent the latest advancements in gene editing, offering researchers greater accuracy and efficiency in correcting genetic mutations without inducing double-strand breaks, which are known to cause genomic instability and unintended mutations. Unlike traditional CRISPR approaches that rely on double-strand breaks and homology-directed repair, base and prime editors introduce precise modifications with a safer profile, reducing the risk of off-target effects and unwanted genetic disruptions.
Until now, obtaining high-quality base and prime editing nucleases required extensive optimization, hindering accessibility for many researchers. GenScript has successfully launched the first off-the-shelf base and prime editing nucleases, providing a ready-to-use solution that accelerates genetic research and therapeutic development.
Base editing and prime editing are innovative gene-editing technologies derived from CRISPR-Cas systems, designed to introduce precise nucleotide changes without generating double-stranded DNA breaks.
Base editors utilize a catalytically impaired Cas9 (nCas9 or dCas9) fused with a deaminase enzyme to convert specific DNA bases without disrupting the DNA strand. This system enables the direct conversion of cytosine (C) to thymine (T) or adenine (A) to guanine (G) in a programmable manner. Base editing provides a highly efficient, low-risk approach for correcting point mutations, making it particularly valuable for therapeutic applications targeting single-nucleotide variations.
Prime editors build upon CRISPR technology by incorporating a reverse transcriptase enzyme fused to a Cas9 nickase (nCas9). This system uses a prime editing guide RNA (pegRNA) that directs both the Cas9-mediated targeting and the template for new DNA synthesis. Unlike traditional gene-editing approaches, prime editing allows for precise insertions, deletions, and base substitutions without requiring donor DNA templates or generating unwanted double-strand breaks.
First-in-Market Solution
The first commercially available, ready-to-use BE and PE nucleases, eliminating the need for extensive optimization.
Comprehensive Product Line
Besides BE, we covers nearly all PE variants, suitable for various applications.
High Purity & Quality
Manufactured with over 90% purity to ensure reliability and consistency.
Multiple Concentrations Available
Offering concentrations from 30 µg to milligram levels to accommodate the needs of different cell types.
GenScript’s base and prime editing nucleases originate from Dr. David Liu’s lab, with patents owned by the Broad Institute. We are proud to license these technologies to provide researchers with high-quality gene-editing solutions. Our products are available for research use only (RUO). For inquiries regarding downstream commercialization, please contact us for legal guidance.
Prime editor
Your search returns no product results. Please explore our custom peptide synthesis solutions.
Base Editor
Your search returns no product results. Please explore our custom peptide synthesis solutions.
Jack Castelli
Fred Hutchinson Cancer Center
"The people at GenScript have been tremendously helpful in providing materials for our lab. We've been able to test novel CRISPR systems such as prime editing and PASSIGE in a timely manner thanks to their work. I would recommend their services for your editing needs."
MariaMorello Mirave
Karolinska Institutet
"We are very pleased with the editing efficiency using base editors from GenScript, we got up to 100% KO!"
Gene editing efficiency in Jurkat cells using ABE8e RNP
High A to G conversion across different doses
ABE8e protein effectively knocks out B2M protein
Gene editing efficiency in HEK293T cells using PE7 RNP at 50 pmol
PE7 mediated targeted 5 bp deletions at the HEK3 locus in HEK293 cells
No significant impact on cell viability